The yale university experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): Analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology

Breast Journal

Volumn 15, Issue 6, 2009, Pages 571-578

  Moran, Meena S ^a   Yang, Qifeng ^b,c   Haffty, Bruce G ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Bcl 2; Breast conservation therapy; COX 2; Invasive lobular breast cancer; P53; Radiation

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; BREAST CONSERVATION TREATMENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CAUSE SPECIFIC SURVIVAL; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DATA BASE; FAMILY HISTORY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE DUCTAL CARCINOMA; INVASIVE LOBAR CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; OBSERVER VARIATION; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RADIATION DOSE; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOOXYGENASE 2; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449725396     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00833.x     Document Type: Article

References (36)

1. 1. Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 2005;242:281-289 (Pubitemid 41033446)
2. 2. Vo TN, Meric-Bernstam F, Yi M, et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006;192:552-555 (Pubitemid 44344191)
3. Gill HK, Berg WA. Case 39: invasive lobular carcinoma. Radiology 2001;221:132-136
4. Hilleren DJ, Andersson IT, Lindholm K, Linnell FS. Invasive lobular carcinoma: mammographic findings in a 10-year experience. Radiology 1991;178:149-154
5. 5. Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer 1994; 73:1673-1677 (Pubitemid 24085268)
6. White J, Gustafson G, Wimbish K. Conservative surgery and radiation therapy for infiltrating lobular carcinoma of the breast. Cancer 1994;74:640-647
7. 7. Hussien M, Lioe TF, Finnegan J, Spence RA. Surgical treatment for invasive lobular carcinoma of the breast. Breast 2003; 12:23-35. (Pubitemid 36395483)
8. du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991;17:251-257
9. 9. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys 2006;66: 1320-1327 (Pubitemid 44778948)
10. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975;36:1-85.
11. Lesser ML, Rosen PP, DW K. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982;91:234-240
12. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998;186:416-422
13. 13. Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996;77:113-120 (Pubitemid 26002745)
14. 14. Molland J, Donnellan M, Janu N, Carmalt H, Kennedy C, Gillett D. Infiltrating lobular carcinoma - a comparison of diagnosis, management and outcomes with infiltrating duct carcinoma. Breast 2004;13:389-396 (Pubitemid 39549788)
15. Takegara M, Tamura M, Kameda H. Examination of breast conserving therapy in lobular carcinoma. Breast Cancer 2004;11: 69-72.
16. 16. Moore MM, Borossa G, Imbrie JZ, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg 2000;231:877-882 (Pubitemid 30350246)
17. van den Broek N, van der Sangen M, van de Polle-Franse L, van Beek M, Nieuwenhiujzen G. Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer. Breast Cancer Res Treat 2007;105:63-68
18. 18. Horn PL, Thompson WD. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer 1988;62:412-424 (Pubitemid 18172611)
19. 19. Peiro G, Bornstein BA, Connolly JL, et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2000;59:49-54. (Pubitemid 30153897)
20. 20. de la Rochefordiere A, Asselain B, Scholl S, et al. Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. Int J Radiat Oncol Biol Phys 1994;30:35-41. (Pubitemid 24291111)
21. 21. Haffty BG, Perrotta PL, Ward B, Moran M, Beinfield M, McKhann CF. Conservatively treated breast cancer: outcomes by histologic subtype. Breast 1997;3:7-14. (Pubitemid 27157092)
22. 22. Mate TP, Carter D, Fischer DB, Hartman PV, McKhann CF, Merino M. A clinical and histopathologic analysis of conservative surgery and radiation therapy in stage I and II breast cancer. Cancer 1986; 58:1995-2002. (Pubitemid 16008774)
23. 23. Schnitt SJ, Connolly JL, Recht A, Silver B, Harris JR, et al. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 1989;64:448-454 (Pubitemid 19180408)
24. 24. Santiago RJ, Harris EE, Qin L, Hwang WT, Solin LJ. Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 2005;103:2447-2454 (Pubitemid 40800521)
25. 25. Salvadoři B, Biganzoli E, Veronesi P, Saccozzi R, Rilke F, et al. Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg 1997;84:106-109 (Pubitemid 27033122)
26. Weiss MC, Fowble BL, Solin LJ, Yeh IT, Schultz DJ. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int J Radiat Oncol Biol Phys 1992;23:941-947
27. 27. Kurtz JM, Jacquemier J, Torhorst J, et al., et al. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer 1989;63:1630-1635 (Pubitemid 19093296)
28. Haffty BG, Yang Q, Moran MS, et al. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in earlystage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 2008; 71:1006-1013
29. Moran MS, Harris LN, Haffty BG. Differences between African American (AA) and Caucasian patients treated with conservative surgery and radiation therapy (CS+RT) for early stage breast cancer (abstract). Int J Radiat Oncol Biol Phys 2007;69(Suppl): S4-5.
30. Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cane Res Treat 2009;115: 343-348
31. 31. Kim JH, Bossuyt V, Ponn T, et al. Cyclooxygenase-2 expression in postmastectomy chest wall relapse. Clin Cancer Res 2005;11:5199-5205 (Pubitemid 41003707)
32. 32. Jansen RL, Joosten-Achjanie SR, Volovics A, et al. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res 1998;18:4455-4462 (Pubitemid 29043676)
33. Daidone MG, Silvestrini R, Luisi A, et al. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995;61:301-305
34. 34. Silvestrini R, Daidone MG, Benini E, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-2013 (Pubitemid 27006633)
35. 35. Hammock L, Lewis M, Phillips C, Cohen C. Strong HER2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003;34:1043-1047 (Pubitemid 37315257)
36. McDonald W, Chen Y, Zaloudek C, et al. c-erbB-2 (HER2/neu)in infiltrative lobular carcinoma: dissociation between immunohistochemistry and fluorescence in-situ hybridization. Mod Pathol 2003;16:40A. (Abstract 170).